KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Opko Health (OPK) EBITDA (2016 - 2025)

Opko Health (OPK) has disclosed EBITDA for 16 consecutive years, with $28.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 185.7% year-over-year to $28.4 million, compared with a TTM value of -$50.7 million through Dec 2025, up 66.66%, and an annual FY2025 reading of -$50.7 million, up 66.66% over the prior year.
  • EBITDA was $28.4 million for Q4 2025 at Opko Health, down from $48.1 million in the prior quarter.
  • Across five years, EBITDA topped out at $48.1 million in Q3 2025 and bottomed at -$87.8 million in Q3 2022.
  • Average EBITDA over 5 years is -$28.4 million, with a median of -$44.2 million recorded in 2022.
  • The sharpest move saw EBITDA plummeted 977.86% in 2024, then surged 238.02% in 2025.
  • Year by year, EBITDA stood at -$63.1 million in 2021, then increased by 12.39% to -$55.3 million in 2022, then fell by 24.92% to -$69.0 million in 2023, then soared by 52.0% to -$33.1 million in 2024, then surged by 185.7% to $28.4 million in 2025.
  • Business Quant data shows EBITDA for OPK at $28.4 million in Q4 2025, $48.1 million in Q3 2025, and -$60.0 million in Q2 2025.